Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Targeting Thrombopoietin/MPL Signaling to Mitigate JAK2V617F-Driven Cardiac Microvascular Disease.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: September 03, 2026
Why rock the boat if sailing is smooth: Time to reconsider target doses in heart failure with reduced ejection fraction.
Journal: The American journal of medicine
Published: May 21, 2026
Novel murine models of hematopoietic-endothelial crosstalk in JAK2V617F-associated cardiovascular disease.
Journal: The American journal of pathology
Published: May 08, 2026
Targeting TPO/MPL Signaling to Mitigate JAK2V617F-driven Cardiac Microvascular Disease.
Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026
When Less Is Enough: Lowest Effective Dose in Clinical Practice.
Journal: The American journal of medicine
Published: March 15, 2026
Mavacamten in Hypertrophic Cardiomyopathy: Getting Safety Right When the Buffer Is Small.
Journal: JACC. Asia
Published: March 12, 2026
Lowest effective doses and intermittent dosing of statins.
Journal: The American journal of medicine
Published: February 05, 2026
Contemporary non-invasive imaging for coronary artery disease.
Journal: Lancet (London, England)
Published: December 01, 2025
Cognitive Decline Overshadows Lifespan Gain: Alzheimer's Disease Demands Priority Over Longevity Research.
Journal: The American journal of medicine
Published: June 05, 2025
Dexrazoxane makes doxorubicin-induced heart failure a rare event in sarcoma patients receiving high cumulative doses.
Journal: Cardio-oncology (London, England)
Published: December 13, 2024
Body Surface Area in Obesity: Clinical Challenges and Call for Improvements.
Journal: Annals of internal medicine
Published: November 11, 2024
Last Updated: 09/26/2026